This process, which has been patented, is quite simple to set-up and robust in terms of reproducibility.
It allows the production of homogenous ADCs with a DAR control of 2:1 or 4:1 antibody/toxin ratios, in minimum synthesis steps.
Furthermore, in vitro studies comparing the anti-HER-2 activity in vitro of a commercial ADC (T-DM1) and its equivalent produced according to our own technique have revealed a similar cytotoxic activity.
THE TECHNOLOGY IS AVAILABLE FOR LICENCE OR OTHER FORMS OF COLLABORATIONS TO
ANYONE INTERESTED TO DEVELOP THEIR OWN ADC(S).